


ERYTHROSE SESQUI-ACETALS AS ELECTROPHILES. 2-DEOXY-C-NUCLEOSIDES FROM D-GLUCOSE.

Robin Polt* and Thusitha Wijayarathne


Chemistry Department, University of Arizona, Tucson, Arizona 85721

Summary: Cleavage of glucosides with NaIO_4 in MeOH furnishes sesqui-acetals (protected dialdehydes). Olefination of these substrates, followed by endocyclic oxymercuration-demercuration furnishes substituted tetrahydrofurans (1,2-dideoxy-1-aryl-D-ribofuranoses). Proper choice of protecting groups can affect the face selectivity of the oxymercuration step to provide only the desired β -C-anomer.


There has been considerable interest in C-nucleosides and various analogs as drugs, and for incorporation into DNA duplexes to examine the factors affecting helix stability.¹⁻³ Strong antibiotic, antitumor, and antiviral activities⁴ have been associated with C-nucleosides which may replace essential metabolites² (inhibitors or anti-metabolites), or as substitutes for essential metabolites (RNA/DNA terminators). Many naturally occurring C-nucleoside analogs have been isolated and synthesized⁵ e.g. pseudouridine, showdownmycin, and formycin.



Pseudouridine




Showdownmycin




Formycin

Our concern with this class of compounds stems from our interest in 4-carbon chiral building blocks.⁶ Glucose provides access to D-erythrose compounds via oxidative removal of two carbons.⁷ By retaining the two carbons which are oxidatively cleaved as a glyoxal acetal-sesqui-acetal (*c.f.* the related "dialdehydes"⁸), we have simplified the isolation of a fully-protected erythrose derivative.

The carbohydrate precursors arabinose,^{9a} xylose,^{9b} glucose,^{5a,9c} glyceraldehyde,^{9d,e} and ascorbic acid^{9f} have been used previously for the synthesis of the deoxypentafuranose ring system. In 1979 Rapoport¹⁰ synthesized 3,5-ethylidene 2-deoxy-ribose from 2,4-ethylidene erythrose. We have utilized a similar approach to produce 2-deoxy-C-nucleosides. Starting with the benzylidene glucoside **1**, NaIO_4 oxidation¹¹ in *anhydrous methanol* provided the crystalline sesqui-acetal **2** (m.p. 150-152°) in ~70% yield. (Scheme 1)




Treatment of **2** with the benzylidene Wittig generated in THF with NaNH_2 provided good yields of a mixture of isomeric bis-olefins. The exocyclic acetal, now allylic, underwent selective cleavage in aqueous acidic THF to yield the two styrene isomers **3a** and **3b** (Scheme I). Compounds **4** and **5** were prepared in a similar fashion from **2** using the methylene Wittig reagent, and the Horner-Emmons reagent prepared from dimethyl(2-oxopropyl)phosphonate in 43% and 57%, respectively. Olefination with more basic methoxy- and benzyloxy-substituted Wittig reagents failed due to β -elimination of the exocyclic acetal from the erythrose substrate.



Although Henbest reported a Hg^{++} promoted ring closure [5-endo-trig] of a bis-homo-allylic alcohol in 1959,¹² the intervening years provide almost no examples of such cyclizations.¹³ Several attempts to cyclize **3a** using various solvents and Hg^{++} salts provided no trace of the desired C-nucleoside.

(Scheme II) Cleavage of the benzylidene ring provided the triol **6**, which yielded three of the four possible products arising from cyclization of the 1° alcohol upon treatment with $\text{Hg}(\text{OAc})_2$ in MeOH. We therefore silylated the offending 1° alcohol, and proceeded. The olefinic siloxy diol **7** was treated with $\text{Hg}(\text{OAc})_2$ in THF at 0°C for 30 minutes, followed by NaBH_4 to provide the desired ribofuranose compounds **8a** and **8b** in 66% yield as a 2:3 ratio of α/β anomers. The anomers were separated by flash and fully characterized (IR, ^1H , ^{13}C , MS & $[\alpha_D]$). Cleavage of the silyl group from **8b** provided the known³ deoxy-C-nucleoside **12**. (see Scheme III)

Thus, in the absence of a more favorable cyclization pathway, the anti-Baldwin cyclization¹⁴ proceeds without difficulty. We reasoned that a 1,3-diol protecting group more flexible than benzylidene might permit 5-endo-trig cyclization, and influence the α/β anomer ratio (Scheme III). Use of the tetraisopropylidisiloxane (TIPDS) protecting group¹⁵ not only accomplished these goals, but increased the yield of the desired *trans*-olefin as well. (The *cis*-isomer does not cyclize.¹²) The glucoside **9** provided a single geometric isomer **10** upon oxidation, olefination, and selective hydrolysis. Cyclization as before provided a single cyclic product **11**, which also produced diol **12** upon desilylation.



SCHEME III

We attribute this dramatic change in α/β ratio to a decrease in the dihedral angle between the hydroxyl and the styryl group, coupled with decreased access to one face of the styrene double bond. In effect, the Hg^{++} ion may be directed to one face of the styrene double bond by the hydroxyl,¹³ and away from the other face by the disiloxane moiety, resulting in the high diastereoselectivity.

It is noteworthy that the synthetic approach described in this paper is short and highly convergent. Work is presently underway to extend this methodology to more biologically relevant targets by using heterocyclic Wittig reagents.^{1c,16}

Acknowledgement. We would like to thank Dr. Jaroslav Zajicek for his assistance with the NMR, and the Department of Chemistry at the University of Arizona for the financial support of this work.

References.

1. a) Hanessian, S.; Pernet, A.G. *Adv. Carbohydr. Chem. Biochem.* **1976**, *3*, 111, b) Daves, G.D.; Cheng, C.C. *Prog. Med. Chem.* **1976**, *13*, 303. c) Buchanan, J.G. *Prog. Chem. Org. Nat. Prod. (Fortschritte)* **1983**, *44*, 243, d) Townsend, L.B.; Cupps, T.L.; Wise, D.S. *J. Org. Chem.* **1986**, *51*, 1058.
2. a) Gerzon, K.; de Long, D.C.; Cline, J.C. *Pure Appl. Chem.* **1971**, *28*, 489, b) Robins, R.K.; Revankar, G.R. pp 11-36 in DeClerq, E.; Walker, R.T. (Eds.) *Antiviral Drug Development. A Multidisciplinary Approach*. Plenum Press, New York **1987**.
3. a) Eaton, M.A.W.; Millican, T.A.; Mann, J. *J. Chem. Soc. Perkin Trans. I* **1988**, 545, b) Millican, T.A.; Mock, G.A.; Chauncey, M.A.; Patel, T.P.; Eaton, M.A.W.; Gunning, J.; Cutbush, S.D.; Neidle, S.; Mann, J. *Nucleic Acids Research* **1984**, *12*, 7435.
4. a) Fox, J.J.; Watanabe, K.A.; Bloch, A. *Prog. Nucleic Acid Research Mol. Biol.* **1966**, *5*, 251, b) Suhadolnik, R.J. "Nucleoside Antibiotics," Wiley-Interscience, New York **1970**, c) Suhadolnik, R.J. *Prog. Nucleic Acids Res. Mol. Biol.* **1979**, *22*, 193, d) Buchanan, J.G.; Wightman, R.H. in Sammes, P.G. (Ed.) *Topics in Antibiotic Chemistry* **1982**, *6*, 229, e) Darnall, K.R.; Townsend, L.B.; Robins, R.K. *Proc. Nat. Acad. Sci. U.S.* **1967**, *57*, 548, f) Buchanan, J.G.; Harrison, M.; Wightman, R.H.; Harnden, M.R. *J. Chem. Soc. Perkin Trans. I* **1989**, 925.
5. a) Cohn, W.E. *Biochim. Biophys. Acta* **1959**, *32*, 569, b) Hori, M.; Ito, E.; Takita, T.; Koyama, G.; Takeguchi, T.; Umezawa, H. *J. Antibiotics Ser. A* **1964**, *17*, 96, c) Koyama, G.; Maeda, K.; Umezawa, H.; Iitaka, Y. *Tetrahedron Lett.* **1966**, 597, d) Koyama, G.; Umezawa, H. *J. Antibiotics Ser. A* **1965**, *18*, 175, e) Ogawa, T.; Kikuchi, Y.; Matsui, M.; Ohnui, H.; Kuzuhara, H.; Emoto, S. *Agr. Biol. Chem.* **1971**, *35*, 1825.
6. a) Seebach, D.; Hungerbühler, E. pp 91-171 in Scheffold, R. (Ed.) *Modern Synthetic Methods 1980* Springer Verlag, Berlin **1980**, b) Scott, J.W. pp 1-226 in Morrison, J.D.; Scott, J.W. (Eds.) *Asymmetric Synthesis Vol. 4* Academic Press, New York **1984**, d) Hanessian, S. *Total Synthesis of Natural Products: The 'Chiron Approach'* Pergamon Press, New York **1983**.
7. a) Braggett, N.; Buck, K.W.; Foster, A.B. *J. Chem. Soc. (C)* **1966**, 212, b) Carlson, K.D.; Smith, C.R.; Wolff, I.A. *Carbohydr. Res.* **1970**, *13*, 391, 403, c) Paulsen, H.; Bartsch, W.; Thiem, J. *Chem. Ber.* **1971**, *104*, 2545, d) Andersson, R.; Theander, O.; Westerlund, E. *Carbohydr. Res.* **1978**, *61*, 501, Thiem, J.; Wessel, H.P. *Liebigs Ann. Chem.* **1982**, 595, f) See H. Rapoport, et al., Ref. 10.
8. a) Cadotte, J.E.; Dutton, G.G.S.; Goldstein, I.J.; Lewis, B.A.; Smith, F.; van Cleve, J.W. *J. Am. Chem. Soc.* **1957**, *79*, 691, b) Guthrie, R.D.; Honeyman, J. *J. Chem. Soc.* **1959**, 2441, c) Colbran, R.L.; Guthrie, R.D.; Parsons, M.A. *J. Chem. Soc.* **1960**, 3532.
9. a) Kent, P.W.; Stacey, M.; Wiggins *J. Chem. Soc.* **1949**, 1232, b) Dyatkina, N.B.; Azhayev, A.V. *Synthesis* **1984**, 961, c) Giese, B.; Gröninger, K.S.; Witzel, T.; Korth, H.G.; Sustmann, R. *Angew. Chem. Int. Ed. Engl.* **1987**, *26*, 233, d) Murakami, M.; Mukaiyama, T. *Chem. Lett.* **1982**, 241.
10. Hauske, J.R.; Rapoport, H. *J. Org. Chem.* **1979**, *44*, 2472.
11. a) Schmidt, R.R.; Zimmermann, P. *Tetrahedron Lett.* **1986**, *27*, 481, b) Kiso, M.; Nakamura, A.; Nakamura, J. Tomita, Y.; Hasegawa, A. *J. Carbohydr. Chem.* **1986**, *5*, 335.
12. Henbest, H.B.; Nicholls, B. *J. Chem. Soc.* **1959**, 221.
13. a) Chamberlain, A.R.; Mulholland, R.L.; Kahn, S.D.; Hehre, W.J. *J. Am. Chem. Soc.* **1987**, *109*, 672, b) Reitz, A.B.; Norley, S.O.; Maryanoff, B.E.; Liotta, D.; Monahan, R. *J. Org. Chem.* **1987**, *52*, 4191, c) Takacs, J.M.; Helle, M.A.; Yang, L. *Tetrahedron Lett.* **1989**, *30*, 1777, d) Bartlett, P.A. pp 411-454 in Morrison, J.D. (Ed.) *Asymmetric Synthesis, Vol 3*. Academic Press, New York, **1984**.
14. Baldwin, J.E. *J. Chem. Soc. Chem Commun.* **1976**, 734 and 736.
15. a) Markiewicz, W.T.; Wiewiorowski, M. *Nucl. Acids Res.* **1978**, 185, b) Verdegaaal, C.H.M.; Jansse, P.L.; de Rooij, J.F.M.; van Boom, J.H. *Tetrahedron Lett.* **1980**, *21*, 1571. For a recent example of the use of a siloxy tether to influence the stereochemistry of an intramolecular Diels-Alder reaction, see: c) Craig, D.; Reader, J.C. *Tetrahedron Lett.* **1990**, *31*, 6585.
16. a) Baker, B.R.; Jordaan, J.H. *J. Het. Chem.* **1966**, *3*, 324, b) Klein, R.S.; Fox, J.J. *J. Org. Chem.* **1972**, *37*, 4381.

(Received in USA 23 April 1991)